



1743
JFW

PN0222

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bill Clark et, al. Confirmation No.: 7113
Serial Number: 10/511,960
Filing Date: May 9, 2005
Title: Methods and Compound Mixtures for Determining Protein Activity using NMR Spectroscopy

Request for Corrected Filing Receipt

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please furnish the undersigned with a corrected filing receipt for the above-identified application. The corrections required is as follows:

In the "Applicant(s)" section, please make the following correction to the State, Country of applicants Looker, O'Sullivan and Santos.

~~Cardiff, AUSTRALIA~~ South Wales, United Kingdom

Enclosed is a marked up copy of the Filing Receipt having a mailing date of

June 28, 2005. Any questions can be referred to the undersigned.


Respectfully submitted,

Robert F. Chisholm
Reg. No. 39,939

Amersham Health, Inc.
101 Carnegie Center
Princeton, NJ 08540
(609) 514-6905

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Lori Allaire
Signature Lori Allaire
Date 1-12-06



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/511,960	05/09/2005	2862	1334	PN0222		23	4

CONFIRMATION NO. 7113

36335
 AMERSHAM HEALTH
 IP DEPARTMENT
 101 CARNEGIE CENTER
 PRINCETON, NJ 08540-6231

FILING RECEIPT



OC000000016379368

Date Mailed: 06/28/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Bill Clark, Colgate, WI;
 Klaes Golman, Malmo, SWEDEN;
 Mathilde H. Lerche, Malmo, SWEDEN;
 Mike Looker, Cardiff, AUSTRALIA; SOUTH WALES, UNITED KINGDOM
 Mike O'Sullivan, Cardiff, AUSTRALIA; SOUTH WALES, UNITED KINGDOM
 Albie Santos, Cardiff, AUSTRALIA; SOUTH WALES, UNITED KINGDOM
 Rolf Servin, Malmo, SWEDEN;
 Mikkel Thaning, Malmo, SWEDEN;
 Jan-Henrik Ardenkjaer-Larsen, Malmo, SWEDEN;

Power of Attorney: The patent practitioners associated with Customer Number 36335.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/NO03/00125 04/15/2003

Foreign Applications

NORWAY 20021886 04/19/2002
 NORWAY 20023357 07/11/2002

Projected Publication Date: 10/06/2005

Non-Publication Request: No

Early Publication Request: No

Title

Methods and compound mixtures for determining protein activity using nmr spectroscopy

Preliminary Class

324

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).